News | March 07, 2012

TAVR Credentialing Recommendations Released

TAVR, TAVI, transcatheter aortic valve replacement, recommendations, Credentialing

March 7, 2012 — Four leading heart organizations representing cardiologists and cardiothoracic surgeons released initial recommendations for creating and maintaining transcatheter aortic valve replacement (TAVR) programs. The recommendations are aimed at ensuring optimal care for patients with aortic stenosis, a form of valvular heart disease, as use of the new TAVR procedure grows.

Since the U.S. Food and Drug Administration’s (FDA) approval of TAVR in November 2011, interest in the procedure has quickly grown among cardiologists and cardiothoracic surgeons as well as patients, prompting efforts by professional medical societies to identify institutional and physician credentialing criteria for performing the procedure. The published recommendations represent a joint collaboration of cardiovascular specialty societies, including the American College of Cardiology Foundation (ACCF), the Society for Cardiovascular Angiography and Interventions (SCAI), the American Association for Thoracic Surgery (AATS) and the Society for Thoracic Surgeons (STS).

TAVR is a minimally invasive procedure found by the FDA to be reasonably safe and effective in the treatment of patients with severe aortic stenosis who cannot undergo surgery and have the absence of comorbidities, as described in the FDA label. Prior to the availability of TAVR, patients had few, if any, treatment options for aortic stenosis, which can lead to heart failure and death. During TAVR, physicians use a catheter to thread the replacement valve from a blood vessel in the groin to the heart's diseased aortic valve, which is then replaced with the new valve.

"As new technologies begin to be incorporated into cardiovascular practice, it is the responsibility of the medical societies to work together to develop standards for optimal patient care," said Carl Tommaso, M.D., chair of the document writing committee and medical director of the cardiac catheterization lab, Skokie Hospital, NorthShore HealthSystem, Chicago. "TAVR is a complex procedure that has potential to serve many patients, and it is up to us to deliver the highest standard of care available."

Due to the complexity of the procedure and the rapid rate at which the technology is evolving, defining operator and institutional requirements is a vital step in ensuring optimal program implementation. The authors emphasize a formal collaborative effort between cardiologists and cardiothoracic surgeons as the cornerstone for establishing a successful program, noting that a program without both specialties would be fundamentally deficient. Other factors on which success is based include ensuring patient safety and demonstrated commitment to excellence by the institution and procedural volume requirements.

The recommendations classify operating requirements for those that intend to develop a TAVR program, including credentialing requirements for cardiothoracic surgeons and interventional cardiologists who intend to perform the procedure, and guidance for maintaining approval to perform TAVR. Requirements include:

  • Annual heart (aortic valve) surgery and percutaneous coronary intervention (PCI) volume requirements for institutions;
  • Board certification and procedural requirements for both surgeons and interventional cardiologist;
  • Monitoring of complication rates and institutional follow-up;
  • Participation in a national registry that will include enrollment of all patients undergoing TAVR with continued tracking of outcomes; and
  • Commitment to a heart team concept that is led by the surgeon and interventional cardiologist and made up of a formal collaborative effort among all medical team members. In all TAVR procedures, the interventional cardiologist and surgeon must both be present during the entire procedure ensuring joint participation and optimal patient-centered care.

"Maintaining high standards and a focus on quality improvement is at the core of what we do, for the sake of patients and their safety," said R. Morton Bolman, M.D., co-chair of the document writing committee, chief of the division of cardiac surgery at Brigham and Women's Hospital, and professor of surgery at Harvard Medical School. "This is emphasized in the paper released, as is the need for this to be a dynamic document that we will revisit in the future as the technology evolves, experience grows and data accumulate."

Watch the VIDEO “How to Build An Integrated Heart Team.” Brijeshwar Maini, M.D., and Brian Bethea, M.D., from Tenet Florida’s structural heart program, explain the importance of building a good heart team and how that team should interact. 

For more information: www.scai.org, www.aats.org, www.cardiosource.org/ACC, www.sts.org

Related Content

Ancora Heart Announces Positive Interim Analysis of AccuCinch Ventricular Repair System for Heart Failure
News | Heart Valve Technology | September 24, 2018
Ancora Heart Inc. announced positive clinical data from the company’s recently expanded U.S. early feasibility study...
Medtronic Announces TAVR Study of Aortic Stenosis Patients With Bicuspid Valves
News | Heart Valve Technology | September 19, 2018
The U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) to initiate a new...
4C Medical's AltaValve First-in-Human Experience to be Presented at TCT 2018
News | Heart Valve Technology | September 17, 2018
September 17, 2018 — 4C Medical Technologies Inc.
Gore Acquires Pipeline Medical Technologies Inc.
News | Heart Valve Technology | September 06, 2018
W. L. Gore & Associates Inc. (Gore) announced the acquisition of Pipeline Medical Technologies Inc., a privately...
The Edwards Lifesciences Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May.

The Edwards Cardioband Tricuspid Valve Reconstruction System received the European CE mark approval in May, becoming the first transcatheter tricuspid repair device to be approved in the world.

Feature | Heart Valve Technology | August 21, 2018 | Jeff Zagoudis
The tricuspid valve has been dubbed “the forgotten valve” by many practitioners in the interventional cardiology spac
Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Overlay Init